Document text
Principal Investigator: Chunling Dai
Organization: POP BIOTECHNOLOGIES, INC
Fiscal Year: 2023
Award: $248,855
Funding agency: National Institute on Aging
Project Summary/Abstract
Alzheimer’s disease (AD) currently affects ~6.2 million Americans, and this number is projected to increase to
14 million by 2060 unless novel treatments or interventions to prevent or delay the onset of AD are identified.
Harnessing the immune system to prevent or remove Aβ and/or tau pathologies represents a promising disease-
modifying therapeutic approach for the treatment of AD. Currently, all the previous and ongoing immunotherapy
studies target only one epitope of either Aβ or tau protein. Because most AD cases are multifactorial, and
sporadic AD is caused by multiple mechanisms, it is unlikely that a single target will be sufficient to stop or reduce
the progression of AD. Based on the role of Aβ and tau in the pathogenesis of AD, immunotherapy
simultaneously targeting multiple epitopes of both Aβ and tau may present a promising approach for AD drug
development. The long-term objective of the proposed project is to develop a novel, effective vaccine for AD.
The specific goal of this project is to develop a multivalent "mosaic" vaccine, termed SNAP-AD, targeting multiple
epitopes of Aβ and tau simultaneously with the spontaneous nanoliposome antigen particle (SNAP) platform and
to investigate its therapeutic effects for treating AD in a transgenic mouse model. Our working hypothesis is that
immunotherapy simultaneously targeting the multiple epitopes of both Aβ and tau is a promising approach for
developing effective AD therapeutics. To test this novel hypothesis, we propose three specific aims: (1)
Formulate and characterize SNAP-AD, a mosaic nanoparticle vaccine comprising three tau and two Aβ peptide
epitopes. POP BIO will formulate and characterize the pentavalent SNAP-AD vaccine simultaneously targeting
tau at one N-terminal region (Tau 6-18), one mid-region (Tau 184-195), and one C-terminal region (pS396/S404),
as well as N-terminal Aβ (1-14) and N-terminal pyroglutamate Aβ (pE3-14), and develop a manufacturing method
with reproducible batch-to-batch characterization and the protocols to quantify each peptide and immunogenic
lipid component. (2) Assess SNAP-AD for immune interference, Th1-biased cellular response,
neuroinflammation, and antibodies’ durability. Immune interference will be assessed amongst the 5-plex
immunogens, and if observed, possible ramification methods will be tested. Cellular responses, Th1/Th2 bias of
the antibody response, and the antibodies’ durability induced by SNAP-AD will be probed. (3) Determine SNAP-
AD efficacy using the 3xTg-AD mouse model. Ten-month-old 3xTg-AD mice and age-matched wild-type mice
will be immunized with SNAP-AD and boosted twice with a four-week interval. One month after the third dose of
immunization, behavioral tests, including general behavior, anxiety, locomotor activity, and cognitive function,
will be conducted, and Aβ and tau pathology will be investigated both biochemically/immunohistochemically. The
proposed studies will reveal whether the multivalent immunotherapy approach has promising therapeutic effects
on AD pathologies and cognitive impairment. A positive outcome of this project would potentially lead to a novel
vaccine for the treatment of AD, which will improve the quality of life of individuals with AD.
Terms: <2019-nCoV vaccine><3xTg><3xTg-AD mice><3xTg-AD mouse><AD dementia><AD pathology><AD related dementia><ADRD><Affect><Age><Alzheimer Type Dementia><Alzheimer Vaccines><Alzheimer beta-Protein><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Amyloid beta-Protein><Alzheimer's Disease><Alzheimer's amyloid><Alzheimer's and related dementias><Alzheimer's disease and related dementia><Alzheimer's disease and related disorders><Alzheimer's disease or a related dementia><Alzheimer's disease or a related disorder><Alzheimer's disease or related dementia><Alzheimer's disease pathology><Alzheimer's disease related dementia><Alzheimer's disease therapeutic><Alzheimer's pathology><Alzheimer's therapeutic><Alzheimers Dementia><Amentia><American><Amyloid (Aβ) plaques><Amyloid Alzheimer's Dementia Amyloid Protein><Amyloid Beta-Peptide><Amyloid Plaques><Amyloid Protein A4><Amyloid beta-Protein><Amyloid β><Amyloid β-Peptide><Amyloid β-Protein><Animals><Antibodies><Antibody Response><Antigenic Determinants><Antigens><Anxiety><Aβ><Basic Research><Basic Science><Behavior><Binding Determinants><Biochemical><Biotech><Biotechnology><Brain><Brain Nervous System><C-terminal><COVID-19 vaccine><COVID19 vaccine><Causality><Child Development Disorders><Clinical Trials><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Collaborations><Dementia><Developmental Disabilities><Disease><Disorder><Disturbance in cognition><Dose><Drug Kinetics><Drugs><Encephalon><Epitopes><Etiology><Exhibits><Goals><Health><Human><Immune><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immune mediated therapy><Immune system><Immunes><Immunization><Immunize><Immunodeficiency and Immunosuppression Disorders><Immunologic Diseases><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunologically Directed Therapy><Immunotherapy><Impaired cognition><Individual><Institution><Intervention><Intervention Strategies><Lipids><Liposomal><Liposomes><Locomotor Activity><MT-bound tau><Medication><Methods><Mice><Mice Mammals><Modern Man><Motor Activity><Murine><Mus><N-terminal><NH2-terminal><Nature><Neuritic Plaques><Neurofibrillary Tangles><New York><Outcome><Pathogenesis><Pathology><Peptides><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacokinetics><Phase><Phase 2 Clinical Trials><Phase I Study><Phase II Clinical Trials><Preventive><Primary Senile Degenerative Dementia><Proteins><Protocol><Protocols documentation><Pyroglutamate><QOL><Quality of life><Reproducibility><Research><Rodent Model><Role><SARS-CoV-2 vaccine><SARS-CoV2 vaccine><SARS-coronavirus-2 vaccine><Safety><Senile Plaques><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Societies><Surface><System><Technology><Testing><Therapeutic><Therapeutic Effect><Transgenic Mice><Vaccines><Wild Type Mouse><a beta peptide><aberrant tau phosphorylation><abeta><abnormal tau hyperphosphorylation><abnormal tau hypophosphorylation><abnormally hyperphosphorylated tau><abnormally hyperphosphorylated tau protein><abnormally hypophosphorylated tau><abnormally hypophosphorylated tau protein><abnormally phosphorylated brain tau><abnormally phosphorylated neurofibrillary tau><abnormally phosphorylated tau><ages><amyloid beta><amyloid beta plaque><amyloid-b plaque><amyloid-b protein><aβ plaques><behavior test><behavioral test><beta amyloid fibril><causation><cognitive dysfunction><cognitive function><cognitive loss><cored plaque><corona virus disease 2019 vaccine><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><develop a vaccine><develop vaccines><development of a vaccine><diffuse plaque><disease causation><drug development><drug/agent><extracellular><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunogenic><improved><innovate><innovation><innovative><interventional strategy><manufacture><microtubule bound tau><microtubule-bound tau><mosaic><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano-sized particle><nanoliposomal><nanoliposome><nanoparticle><nanosized particle><neural inflammation><neurofibrillary degeneration><neurofibrillary lesion><neurofibrillary pathology><neuroinflammation><neuroinflammatory><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><new vaccines><next generation vaccines><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><novel vaccines><particle><phase 1 study><phase 3 evaluation><phase 3 testing><phase II protocol><phase III evaluation><phase III testing><pre-clinical study><preclinical study><prevent><preventing><primary degenerative dementia><response><senile dementia of the Alzheimer type><social role><soluble amyloid precursor protein><tangle><tau><tau Proteins><tau factor><therapeutic target><therapeutic vaccine><therapeutically effective><treatment vaccines><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine for novel coronavirus><vaccine for the treatment><vaccine for treatment><wildtype mouse><τ Proteins>